Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients

Figures & data

Figure 1 Patient flow chart.

Table 1 Patients’ baseline characteristics

Parameter	Aliskiren group	Aliskiren-withdrawal group	P value
Number	11	10
Age (years)	66.3 ± 7.4	67.2 ± 8.1	0.56
Gender
Male	7	5
Female	4	5
BMI (kg/m^2)	23.2 ± 3.0	23.8 ± 3.1	0.42
Time on dialysis (weeks)	2.9 ± 0.2	2.8 ± 0.2	0.51
Average time of the dialysis (hours)	4.0 ± 0.2	4.0 ± 0.3	0.63
Average ultrafiltration (kg/hours/HD section)	2.8 ± 1.1	2.7 ± 1.4	0.81
Duration of hemodialysis (years)	6.9 ± 7.2	6.8 ± 6.2	0.76
Initial nephropathy
Chronic glomerulonephritis	2	2
Diabetic nephropathy	7	4
ANCA-associated glomerulonephritis	0	1
Drug nephropathy	0	1
Malignant hypertension	1	0
Unknown	1	2
SBP (mmHg)	175.0 ± 18.0	171.0 ± 13.0	0.30
DBP (mmHg)	80.0 ± 11.0	80.0 ± 14.0	0.89
HR (beats/minute)	78.0 ± 12.0	76.0 ± 10.0	0.91
PRA (ng/mL/hr)	2.3 ± 2.6	3.3 ± 2.9	0.41
ATI (pg/mL)	909.1 ± 902.5	999.1 ± 844.6	0.82
ATII (pg/mL)	41.5 ± 45.8	30.6 ± 36.7	0.56
Ald (pg/mL)	163.5 ± 214.3	97.2 ± 57.5	0.58
BNP (pg/mL)	248.9 ± 197.2	425.3 ± 207.3	0.06
d-ROM (U.CARR)	386.6 ± 123.1	402.3 ± 69.0	0.72

Abbreviations: BMI, body mass index; HD, hemodialysis; ANCA, SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PRA, plasma renin activity; ATI, angiotensin I; ATII, angiotensin II; Ald, aldosterone; BNP, brain natriuretic peptide; d-ROM, diacron-reactive oxygen metabolite; U.CARR, Carratelli units.

Figure 2 Changes in systolic blood pressure and diastolic blood pressure from baseline (week 0) to month 20 in the aliskiren group and the aliskiren-withdrawal group.

Figure 3 Changes in plasma renin activity (PRA), angiotensin I (AT I), angiotensin II (AT II), and aldosterone (Ald) from baseline to month 2 and month 20 in the aliskiren group and the aliskiren-withdrawal group.

Figure 4 Changes in brain natriuretic peptide (ΔBNP) and diacron-reactive oxygen metabolite (Δd-ROM) from baseline to month 2 and month 20 in the aliskiren group and the aliskiren-withdrawal group.